Guest blog by Babirye Zubaina, Research Nurse, CAMO-Net Travel Grant Awardee, Infectious diseases Institute, Uganda Hub
From the 13th to 17th July 2025, I had the privilege of attending the 13th International AIDS Society (IAS) Conference on HIV Science held in Kigali, Rwanda, with support from the CAMO-Net Travel Grant. The conference brought together several thousand participants from across the globe,including scientists, policymakers, programme implementers, Academicians, Journalists and advocates dedicated to advancing the global HIV/AIDS response. This experience was enriching and transformative, providing deep insights into the latest scientific breakthroughs, ongoing challenges and innovative strategies shaping the future of HIV prevention treatment and care.
Advances in HIV Science.
The IAS 2025 provided an exceptional platform to engage with global experts and explore groundbreaking developments in HIV Science. A major highlight was the emphasis on long acting HIV prevention technologies, which are revolutionizing adherence and accessibility.
Key innovations included:
- Lenacapavir (LEN)—a twice yearly injectable PrEP drug recently endorsed by the WHO;
- Injectable Cabotegravir (CAB-LA)—demonstrating strong real-world effectiveness;
- MK-8527—a promising oral pill under study in several countries including Uganda and this could represent a paradigm shift from the injectable formulations.
These innovations among others are reshaping HIV prevention, particularly among key populations that face unique adherence challenges.
Antibiotic Use and Antimicrobial Resistance
Although HIV science was the central focus, some of the sessions tackled the
use of antibiotics in HIV-related care and the broader challenge of Antimicrobial resistance (AMR)—a rapidly growing global health crisis undermining decades of progress in infectious disease control. A key topic was Doxycycline Post-Exposure Prophylaxis(doxyPEP), an antibiotic used after sexual exposure to prevent bacterial Sexually Transmitted Infections (STIs) such as gonorrhea, chlamydia & syphilis.
Evidence presented showed that doxyPEP is highly effective against chlamydia
and syphilis but has variable effectiveness against gonorrhea. Experts emphasized the importance of balancing doxyPEP’s public health benefits of doxyPEP with the potential risk of accelerating antibiotic resistance especially in Neisseria Gonorrhea infections.
HIV-TB Co-Infection Management
Another major theme was Tuberculosis (TB). TB is one of the most common and challenging HIV Co-infections. Updated WHO guidelines were presented, recommending a three-month preventive regimen of rifapentine and isoniazid(3HP). Discussions also explored drug-drug interactions between emerging HIV medications like LEN and TB antibiotics like rifampicin and rifabutin, highlighting the need for integrated pharmacological management in co-infected patients.
Broader AMR Concerns
A WHO report presented at the conference revealed that one in every six laboratory-confirmed bacterial infections globally in 2023 was resistant to antibiotics. This alarming statistic underscored the urgency of promoting responsible use of antibiotics across all health sectors, robust surveillance and
cross-sectoral antimicrobial stewardship.
These conversations demonstrated that HIV programs and AMR control efforts
are deeply interconnected. Both require strong and continuous surveillance systems, targeted implementation among high-risk populations, rational medicine use and sustained investment in research, innovation and capacity building.
African Leadership and Innovation
IAS 2025 also highlighted Africa’s expanding role in leading health innovation.
The launch of The Africa Cure Consortium exemplified this momentum—an
African-led initiative driving research and fostering scientific collaboration
across the continent.
The conference reaffirmed the importance of Africa-Led research and domestic
investment to ensure sustainability, particularly in light of recent global funding cuts. The same innovative drive that has propelled advances in HIV science must now extend to addressing antimicrobial resistance.
Personal Reflection
Attending IAS 2025 was an eye-opening experience that bridged lessons from the field of HIV with the broader challenge of antimicrobial resistance. The discussions on doxyPEP, TB co-infections, and drug-drug interactions reinforced how interconnected these health priorities are.
As AMR continues to rise, the HIV response offers valuable guidance demonstrating how scientific rigor, innovation, and local leadership can transform global health challenges into opportunities for resilience and progress. The future of infectious disease control will depend on one unifying principle: responsible, evidence-based science; sustainable systems, and Africa-led solutions.



















